Literature DB >> 21956146

Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction.

Michael R Zile1, Shannon M Mehurg, Jazmine E Arroyo, Robert E Stroud, Stacia M DeSantis, Francis G Spinale.   

Abstract

BACKGROUND: microRNAs (miRs) are small noncoding RNAs that recognize and bind to mRNAs and inhibit protein translation or degrade mRNA. Studies in animal models have suggested that miRs play a translational or posttranslational regulatory role in myocardial growth, fibrosis, viability, and remodeling. However, whether specific temporal changes in miRs occur in patients during the left ventricular (LV) remodeling process that follows a myocardial infarction (post-MI) remains unknown. The current pilot study tested the hypotheses that plasma miRs could be reliably measured in post-MI patients and that there is a relationship between temporal changes in specific miRs and post-MI LV structural remodeling. METHODS AND
RESULTS: LV end-diastolic volume (echocardiography) and plasma miR were measured in age-matched referent controls (CTLs, n=12) and post-MI patients (n=12) from day 2 through day 90 post-MI. Selected miRs (miR-1, miR-21, miR-29a, miR-133a, and miR-208) were measured using quantitative reverse transcription-polymerase chain reaction and normalized for endogenous small nuclear RNA U6. After MI, LV end-diastolic volume increased progressively compared with CTL; this was accompanied by time-dependent changes in specific miRs. For example, miR-21 initially decreased 2 days post-MI (0.3 ± 0.1-fold versus CTL; P<0.05), increased 5 days post-MI (2 ± 1-fold versus CTL; P<0.05), and returned to CTL values at later post-MI time points. In contrast, miR-29a increased 5 days post-MI (4 ± 1-fold versus CTL; P<0.05) and then decreased to CTL at later time points. miR-208 increased 5 days post-MI (3 ± 1-fold versus CTL; P<0.05) and remained elevated up to 90 days post-MI.
CONCLUSIONS: A time-dependent change in miRs occurred in post-MI patients, including an early and robust increase in miRs that has affected myocardial growth, fibrosis, and viability. Thus, serially profiling miRs in the plasma of post-MI patients may hold both mechanistic and prognostic significance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21956146      PMCID: PMC3535326          DOI: 10.1161/CIRCGENETICS.111.959841

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  24 in total

1.  Time course of plasma markers of collagen turnover in patients with acute myocardial infarction.

Authors:  A D McGavigan; J Moncrieff; M M Lindsay; P R Maxwell; F G Dunn
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

2.  MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction.

Authors:  Benjamin Meder; Andreas Keller; Britta Vogel; Jan Haas; Farbod Sedaghat-Hamedani; Elham Kayvanpour; Steffen Just; Anne Borries; Jessica Rudloff; Petra Leidinger; Eckart Meese; Hugo A Katus; Wolfgang Rottbauer
Journal:  Basic Res Cardiol       Date:  2010-10-01       Impact factor: 17.165

3.  microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart.

Authors:  Ning Liu; Svetlana Bezprozvannaya; Andrew H Williams; Xiaoxia Qi; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Genes Dev       Date:  2008-11-17       Impact factor: 11.361

4.  Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.

Authors:  Carson S Webb; David D Bonnema; S Hinan Ahmed; Amy H Leonardi; Catherine D McClure; Leslie L Clark; Robert E Stroud; William C Corn; Laura Finklea; Michael R Zile; Francis G Spinale
Journal:  Circulation       Date:  2006-08-21       Impact factor: 29.690

5.  Altered microRNA expression in human heart disease.

Authors:  Sadakatsu Ikeda; Sek Won Kong; Jun Lu; Egbert Bisping; Hao Zhang; Paul D Allen; Todd R Golub; Burkert Pieske; William T Pu
Journal:  Physiol Genomics       Date:  2007-08-21       Impact factor: 3.107

6.  Circulating microRNAs as stable blood-based markers for cancer detection.

Authors:  Patrick S Mitchell; Rachael K Parkin; Evan M Kroh; Brian R Fritz; Stacia K Wyman; Era L Pogosova-Agadjanyan; Amelia Peterson; Jennifer Noteboom; Kathy C O'Briant; April Allen; Daniel W Lin; Nicole Urban; Charles W Drescher; Beatrice S Knudsen; Derek L Stirewalt; Robert Gentleman; Robert L Vessella; Peter S Nelson; Daniel B Martin; Muneesh Tewari
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-28       Impact factor: 11.205

Review 7.  The emerging role of microRNAs in cardiac remodeling and heart failure.

Authors:  Vijay Divakaran; Douglas L Mann
Journal:  Circ Res       Date:  2008-11-07       Impact factor: 17.367

8.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

9.  miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling.

Authors:  Rudy F Duisters; Anke J Tijsen; Blanche Schroen; Joost J Leenders; Viola Lentink; Ingeborg van der Made; Veronica Herias; Rick E van Leeuwen; Mark W Schellings; Paul Barenbrug; Jos G Maessen; Stephane Heymans; Yigal M Pinto; Esther E Creemers
Journal:  Circ Res       Date:  2008-12-18       Impact factor: 17.367

10.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis.

Authors:  Eva van Rooij; Lillian B Sutherland; Jeffrey E Thatcher; J Michael DiMaio; R Haris Naseem; William S Marshall; Joseph A Hill; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-22       Impact factor: 11.205

View more
  56 in total

Review 1.  Circulating microRNAs: novel biomarkers for cardiovascular diseases.

Authors:  Jiahong Xu; Jiangmin Zhao; Graham Evan; Chunyang Xiao; Yan Cheng; Junjie Xiao
Journal:  J Mol Med (Berl)       Date:  2011-12-08       Impact factor: 4.599

Review 2.  Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction.

Authors:  Christian Schulte; Dirk Westermann; Stefan Blankenberg; Tanja Zeller
Journal:  World J Cardiol       Date:  2015-12-26

3.  Clinical relevance of plasma miR-21 in new-onset systemic lupus erythematosus patients.

Authors:  Zhao Ming Tang; Min Fang; Jin Ping Wang; Peng Cheng Cai; Ping Wang; Li Hua Hu
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

Review 4.  The biology of circulating microRNAs in cardiovascular disease.

Authors:  Pil-Ki Min; Stephen Y Chan
Journal:  Eur J Clin Invest       Date:  2015-08       Impact factor: 4.686

Review 5.  MicroRNA208 family in cardiovascular diseases: therapeutic implication and potential biomarker.

Authors:  Ying Huang; Jun Li
Journal:  J Physiol Biochem       Date:  2015-04-04       Impact factor: 4.158

Review 6.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

Review 7.  Epigenetic mechanisms underlying cardiac degeneration and regeneration.

Authors:  Pankaj Chaturvedi; Suresh C Tyagi
Journal:  Int J Cardiol       Date:  2014-02-20       Impact factor: 4.164

8.  Feedback mechanisms for cardiac-specific microRNAs and cAMP signaling in electrical remodeling.

Authors:  Richard Myers; Valeriy Timofeyev; Ning Li; Catherine Kim; Hannah A Ledford; Padmini Sirish; Victor Lau; Yinuo Zhang; Kiran Fayyaz; Anil Singapuri; Javier E Lopez; Anne A Knowlton; Xiao-Dong Zhang; Nipavan Chiamvimonvat
Journal:  Circ Arrhythm Electrophysiol       Date:  2015-05-20

Review 9.  MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases.

Authors:  Osama Abo Alrob; Said Khatib; Saleh A Naser
Journal:  J Physiol Biochem       Date:  2016-12-14       Impact factor: 4.158

Review 10.  MicroRNAs in metabolic disease.

Authors:  Carlos Fernández-Hernando; Cristina M Ramírez; Leigh Goedeke; Yajaira Suárez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.